Accelerate Diagnostics, Inc. (AXDX) earnings
AXDX earnings moved a median of -1.17% by the close. Quarterly and annual AXDX reports and results, each read against the price at its own news timestamp. Back to the AXDX overview →
16 measured AXDX earnings events.
Where these AXDX earnings landedvs 16 measured AXDX earnings reactions
| Middle 50% of AXDX earnings reactions | -3.02% to +0.40% |
|---|---|
| Median reaction (to close) | -1.17% |
| Measured reactions | 16 |
Point-in-time · zero look-ahead
Half of the 16 AXDX earnings events with a measured close landed between -3.02% and +0.40%; 31% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-K/A Accelerate Diagnostics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -2.53% | |
| Form 10-K Accelerate Diagnostics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -4.50% | |
| Accelerate Diagnostics Reports Third Quarter 2024 Financial Results | Press release | — | -4.69% | |
| Form 10-Q Accelerate Diagnostics, For: Sep 30 | SEC filing · Form 10-Q | — | -4.69% | |
| Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results | Press release | -0.80% | +0.00% | |
| Accelerate Diagnostics Reports Second Quarter 2024 Financial Results | Press release | +0.00% | +5.07% | |
| Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results | Press release | — | +2.90% | |
| Form 10-Q Accelerate Diagnostics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +5.07% | |
| Form 10-Q Accelerate Diagnostics, For: Mar 31 | SEC filing · Form 10-Q | — | +0.11% | |
| Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results | Press release | +0.00% | -2.25% | |
| Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results. | Press release | -1.06% | +1.28% | |
| Form 10-K Accelerate Diagnostics, For: Dec 31 | SEC filing · Form 10-K | -2.08% | -8.33% | |
| Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results. | Press release | +6.44% | -1.82% | |
| Accelerate Diagnostics Reports Third Quarter 2023 Results | Press release | +0.00% | -0.52% | |
| Form 10-Q Accelerate Diagnostics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -0.52% | |
| Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results. | Press release | — | -2.39% |
Keep exploring
More AXDX: analyst actions → · SEC filings → · AXDX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AFFYMAX INC (AFFY) | 126 | +0.16% | 53% |
| Synergy CHC Corp. (SNYR) | 126 | -0.06% | 43% |
| GENMAB A/S (GMXAY) | 125 | 0.00% | 38% |
| BIOTRICITY INC (BTCY) | 124 | 0.00% | 38% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.